Related references
Note: Only part of the references are listed.Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report
Susumu Kurihara et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Jianchun Duan et al.
JAMA ONCOLOGY (2020)
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Lee-Shing Chang et al.
ENDOCRINE REVIEWS (2019)
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette et al.
HORMONE AND METABOLIC RESEARCH (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Yucai Wang et al.
JAMA ONCOLOGY (2019)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Fiamma Berner et al.
JAMA ONCOLOGY (2019)
Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature
Ashray Gunjur et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO plus IPI: a systematic review and meta-analysis
Puyuan Xing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome
Giulia Lanzolla et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2019)
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
Isabella Lupi et al.
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS (2019)
Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death antibody insight into the pathogenesis of autoimmune endocrinopathy-
Sumie Okahata et al.
ENDOCRINE JOURNAL (2019)
A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism
Amani Erra et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2019)
Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment
Jose Leon Mengibar et al.
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS (2019)
Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency
Catarina Martins Machado et al.
BMJ CASE REPORTS (2019)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Autoimmune Polyendocrine Syndromes
Eystein S. Husebye et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis
Melissa Sum et al.
PITUITARY (2018)
Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab
Kanako Sakurai et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Rheumatic immune-related adverse events from cancer immunotherapy
Leonard H. Calabrese et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response
Lucien Marchand et al.
Journal of Thoracic Oncology (2017)
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma
Anne-Cecile Paepegaey et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
Li Li et al.
CASE REPORTS IN ONCOLOGY (2017)
Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes
Sung Hye Kong et al.
ACTA DIABETOLOGICA (2016)
A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
Elizabeth Hansen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment
Malik Asif Humayun et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2016)
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
Jared R. Lowe et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Immune-related endocrine disorders in novel immune checkpoint inhibition therapy
Le Min
GENES & DISEASES (2016)
Sex differences in immune responses
Sabra L. Klein et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2015)
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Desiree Schubert et al.
NATURE MEDICINE (2014)
HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: Analysis of the Type 1 Diabetes Genetics Consortium families
Henry Erlich et al.
DIABETES (2008)
Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population
K Hashimoto et al.
HORMONE RESEARCH (2005)
Share Paper
